MapLight's ML-004 Misses Phase 2 Endpoint But Shows Irritability Signal In Adolescents

MapLight Therapeutics said its Phase 2 IRIS study of ML-004 in autism spectrum disorder did not meet the primary endpoint for improving social communication deficits. The failure is a negative read-through for the program and could pressure the stock, though the article only provides topline results and no further data.

Analysis

MapLight Therapeutics said its Phase 2 IRIS study of ML-004 in autism spectrum disorder did not meet the primary endpoint for improving social communication deficits. The failure is a negative read-through for the program and could pressure the stock, though the article only provides topline results and no further data.